Home / Companies / News / Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing

Premium

Edelweiss said it expected 30 per cent profit after tax (PAT) growth for the sector and around 8 per cent growth in revenues for the December quarter

Sohini Das Mumbai

3 min read Last Updated : Jan 11 2021 | 6:10 AM IST

Domestic drug sales in December indicated that the third quarter of the ongoing financial year is going to result in earnings growth recovery for the sector. Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities.

Edelweiss said it expected 30 per cent profit after tax (PAT) growth for the sector and around 8 per cent growth in revenues for the December quarter. On the other hand, analysts at Phillip Capital estimated a 43 per cent earnings growth year-on-year (YoY) (down 2 per

Topics : Coronavirus Sun Pharma Indian pharma Q3 results corporate earnings Cipla Pharma industry Indian Economy

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in